Literature DB >> 31786652

Pre-treatment ADC image-based random forest classifier for identifying resistant rectal adenocarcinoma to neoadjuvant chemoradiotherapy.

Chun Yang1,2,3, Ze-Kun Jiang4, Li-Heng Liu5,6,7, Meng-Su Zeng1,2,3.   

Abstract

OBJECTIVE: To develop a predicting model for tumor resistance to neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal cancer (LARC) by using pre-treatment apparent diffusion coefficient (ADC) image-derived radiomics features.
METHOD: A total of 89 patients with LARC were randomly assigned into training (N = 66) and testing cohorts (N = 23) at the ratio of 3:1. Radiomics features were derived from manually determined tumor region of pre-treatment ADC images. Random forest algorithm was used to determine the most relevant features and then to construct a predicting model for identifying resistant tumor. Stability and diagnostic performance of the random forest model was evaluated with the testing cohort.
RESULTS: The top 10 most relevant features (entropymean, inverse variance, energymean, small area emphasis, ADCmin, ADCmean, sdGa02, small gradient emphasis, age, and size) were determined from clinical characteristics and 133 radiomics features. In the prediction of resistant tumor of the testing cohort, the random forest model constructed based on these most relevant features achieved an area under the receiver operating characteristic curve of 0.83, with the highest accuracy of 91.3%, a sensitivity of 88.9%, and a specificity of 92.8%.
CONCLUSION: The random forest classifier based on radiomics features derived from pre-treatment ADC images have the potential to predict tumor resistance to NCRT in patients with LARC, and the use of predicting model may facilitate individualized management of rectal cancer.

Entities:  

Keywords:  Diffusion-weighted MRI; Drug resistance; Machine learning; Neoadjuvant therapy; Neoplasm; Rectal cancer

Mesh:

Year:  2019        PMID: 31786652     DOI: 10.1007/s00384-019-03455-3

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  18 in total

1.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Authors:  Claus Rödel; Ullrich Graeven; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Dirk Arnold; Ralf-Dieter Hofheinz; Michael Ghadimi; Hendrik A Wolff; Marga Lang-Welzenbach; Hans-Rudolf Raab; Christian Wittekind; Philipp Ströbel; Ludger Staib; Martin Wilhelm; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer; Torsten Liersch
Journal:  Lancet Oncol       Date:  2015-07-15       Impact factor: 41.316

2.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Authors:  Natally Horvat; Harini Veeraraghavan; Monika Khan; Ivana Blazic; Junting Zheng; Marinela Capanu; Evis Sala; Julio Garcia-Aguilar; Marc J Gollub; Iva Petkovska
Journal:  Radiology       Date:  2018-03-07       Impact factor: 11.105

3.  Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.

Authors:  Julio Garcia-Aguilar; Zhenbin Chen; David D Smith; Wenyan Li; Robert D Madoff; Peter Cataldo; Jorge Marcet; Carlos Pastor
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

4.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

5.  Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.

Authors:  A J Breugom; W van Gijn; E W Muller; Å Berglund; C B M van den Broek; T Fokstuen; H Gelderblom; E Kapiteijn; J W H Leer; C A M Marijnen; H Martijn; E Meershoek-Klein Kranenbarg; I D Nagtegaal; L Påhlman; C J A Punt; H Putter; A G H Roodvoets; H J T Rutten; W H Steup; B Glimelius; C J H van de Velde
Journal:  Ann Oncol       Date:  2014-12-05       Impact factor: 32.976

6.  Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI.

Authors:  Ke Nie; Liming Shi; Qin Chen; Xi Hu; Salma K Jabbour; Ning Yue; Tianye Niu; Xiaonan Sun
Journal:  Clin Cancer Res       Date:  2016-05-16       Impact factor: 12.531

7.  Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment.

Authors:  Atthaphorn Trakarnsanga; Mithat Gönen; Jinru Shia; Garrett M Nash; Larissa K Temple; José G Guillem; Philip B Paty; Karyn A Goodman; Abraham Wu; Marc Gollub; Neil Segal; Leonard Saltz; Julio Garcia-Aguilar; Martin R Weiser
Journal:  J Natl Cancer Inst       Date:  2014-09-22       Impact factor: 13.506

Review 8.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

9.  Radiomics-Based Pretherapeutic Prediction of Non-response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

Authors:  Xuezhi Zhou; Yongju Yi; Zhenyu Liu; Wuteng Cao; Bingjia Lai; Kai Sun; Longfei Li; Zhiyang Zhou; Yanqiu Feng; Jie Tian
Journal:  Ann Surg Oncol       Date:  2019-03-18       Impact factor: 5.344

10.  Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors.

Authors:  Yoshihito Nakagawa; Yuki Kuranaga; Tomomitsu Tahara; Hiromi Yamashita; Tomoyuki Shibata; Mitsuo Nagasaka; Kohei Funasaka; Naoki Ohmiya; Yukihiro Akao
Journal:  Cancer Sci       Date:  2019-07-23       Impact factor: 6.716

View more
  6 in total

Review 1.  Rectal MRI radiomics inter- and intra-reader reliability: should we worry about that?

Authors:  Henry C Kwok; Charlotte Charbel; Jayasree Chakraborty; Natally Horvat; Sofia Danilova; Joao Miranda; Natalie Gangai; Iva Petkovska
Journal:  Abdom Radiol (NY)       Date:  2022-04-02

2.  Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.

Authors:  Zheng-Yan Li; Xiao-Dong Wang; Mou Li; Xi-Jiao Liu; Zheng Ye; Bin Song; Fang Yuan; Yuan Yuan; Chun-Chao Xia; Xin Zhang; Qian Li
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

3.  An Ensemble-Based Deep Convolutional Neural Network for Computer-Aided Polyps Identification From Colonoscopy.

Authors:  Pallabi Sharma; Bunil Kumar Balabantaray; Kangkana Bora; Saurav Mallik; Kunio Kasugai; Zhongming Zhao
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

4.  Handcrafted and Deep Learning-Based Radiomic Models Can Distinguish GBM from Brain Metastasis.

Authors:  Zhiyuan Liu; Zekun Jiang; Li Meng; Jun Yang; Ying Liu; Yingying Zhang; Haiqin Peng; Jiahui Li; Gang Xiao; Zijian Zhang; Rongrong Zhou
Journal:  J Oncol       Date:  2021-06-03       Impact factor: 4.375

Review 5.  Emerging applications of radiomics in rectal cancer: State of the art and future perspectives.

Authors:  Min Hou; Ji-Hong Sun
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

6.  A Deep Learning Model to Predict the Response to Neoadjuvant Chemoradiotherapy by the Pretreatment Apparent Diffusion Coefficient Images of Locally Advanced Rectal Cancer.

Authors:  Hai-Tao Zhu; Xiao-Yan Zhang; Yan-Jie Shi; Xiao-Ting Li; Ying-Shi Sun
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.